Table 3.
Number of isolates responsible for invasive pneumococcal disease in adult patients, according to vaccine serotype groups and age groups, from 2015 to 2018.
| Age Group (Years) | Serotype Group 1 | No. of Isolates (%) | CA 2 | |||
|---|---|---|---|---|---|---|
| 2015 | 2016 | 2017 | 2018 | |||
| 18–49 | PCV7 | 8 (7.8) | 14 (16.5) | 12 (10.9) | 8 (8.1) | 0.807 |
| addPCV13 | 23 (22.3) | 19 (22.4) | 15 (13.6) | 22 (22.2) | 0.593 | |
| addPCV15 | 13 (12.6) | 3 (3.5) | 4 (3.6) | 0 (0) | <0.001 | |
| addPCV20 | 35 (34.0) | 28 (32.9) | 44 (40.0) | 42 (42.4) | 0.139 | |
| addPPV23 | 11 (10.7) | 8 (9.4) | 13 (11.8) | 15 (15.2) | 0.286 | |
| NVT | 13 (12.6) | 13 (15.3) | 22 (20.0) | 12 (12.1) | 0.802 | |
| 50–64 | PCV7 | 21 (16.9) | 16 (14.0) | 18 (14.4) | 15 (11.2) | 0.216 |
| addPCV13 | 33 (26.6) | 26 (22.8) | 24 (19.2) | 27 (20.1) | 0.166 | |
| addPCV15 | 2 (1.6) | 7 (6.1) | 7 (5.6) | 7 (5.2) | 0.218 | |
| addPCV20 | 30 (24.2) | 44 (38.6) | 44 (35.2) | 51 (38.1) | 0.041 | |
| addPPV23 | 13 (10.5) | 3 (2.6) | 6 (4.8) | 13 (9.7) | 0.993 | |
| NVT | 25 (20.2) | 18 (15.8) | 26 (20.8) | 21 (15.7) | 0.558 | |
| ≥65 | PCV7 | 53 (17.5) | 44 (14.6) | 39 (11.4) | 41 (12.3) | 0.033 |
| addPCV13 | 74 (24.4) | 75 (24.8) | 90 (26.4) | 77 (23.1) | 0.819 | |
| addPCV15 | 26 (8.6) | 30 (9.9) | 41 (12.0) | 31 (9.3) | 0.584 | |
| addPCV20 | 54 (17.8) | 59 (19.5) | 78 (22.9) | 92 (27.6) | 0.002 | |
| addPPV23 | 23 (7.6) | 27 (8.9) | 30 (8.8) | 23 (6.9) | 0.733 | |
| NVT | 73 (24.1) | 67 (22.2) | 63 (18.5) | 69 (20.7) | 0.183 | |
1 PCV7: serotypes included in the 7-valent conjugate vaccine; addPCV13: additional serotypes included in the 13-valent conjugate vaccine and not present in PCV7—1, 3, 5, 6A, 7F, and 19A; addPCV15: additional serotypes included in the 15-valent conjugate vaccine and not present in PCV13—22F and 33F; addPCV20: additional serotypes included in the 20-valent conjugate vaccine and not present in PCV15—8, 10A, 11A, 12F, and 15B (for the purpose of this paper, we assumed that protection was afforded against IPD by the 15B/C group of isolates); addPPV23: the additional 3 serotypes exclusively present in the 23-valent pneumococcal polysaccharide vaccine—9N, 17F and 20; NVT: serotypes not included in any of the currently available pneumococcal vaccines. 2 CA: Cochran–Armitage test for trend. Values in bold were significant after FDR correction.